{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:01:11Z","timestamp":1793642471087,"version":"4.5.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While T-cell Bispecifics (TCBs) are promising molecules for cancer treatment, their clinical development remains challenging due to Cytokine Release Syndrome (CRS). There is currently no method to accurately predict the doses expected to trigger CRS from pre-clinical data, resulting in the selection of non optimal First-In-Human (FIH) doses, far from the doses expected to show clinical benefit, to address safety concerns. In this work, a retrospective analysis aiming to identify which\n                    <jats:italic>in vitro<\/jats:italic>\n                    assay (focusing on tumor cell killing and cytokine release) is predictive of CRS at the first administration of TCBs developed for oncology indications at Roche is presented. A concentration threshold of C\n                    <jats:sub>max<\/jats:sub>\n                    25-times the\n                    <jats:italic>in vitro<\/jats:italic>\n                    tumor cell killing EC50 from the most sensitive assay (or 96% of the maximum killing effect) has been identified and can be used to guide the selection of clinical dose associated with no CRS. Above this concentration threshold, any CRS without distinction from grades 1\u20133 have been observed. This work demonstrates that\n                    <jats:italic>in vitro<\/jats:italic>\n                    tumor cell killing assay can be used to determine a FIH for TCBs at which no CRS is expected (at least for TCBs similar to the one used in this analysis). It also suggests that CRS events are connected to the intended pharmacological effect (tumor cell killing). This work can guide the selection of TCB FIH clinical doses, allowing higher starting dose compared to the minimum anticipated biological effect approach, therefore increasing patients\u2019 benefit.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01177-9","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:43:21Z","timestamp":1763491401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2581-1086","authenticated-orcid":false,"given":"Apolline","family":"Lef\u00e8vre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-2710","authenticated-orcid":false,"given":"Zinnia P.","family":"Parra-Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8658","authenticated-orcid":false,"given":"I\u00f1aki F.","family":"Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8467-0339","authenticated-orcid":false,"given":"Christophe","family":"Boetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Frances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"9","key":"1177_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00011-013-0645-9","volume":"62","author":"B Lakshmi Narendra","year":"2013","unstructured":"Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res. 2013;62(9):823\u201334. https:\/\/doi.org\/10.1007\/s00011-013-0645-9.","journal-title":"Inflamm Res"},{"issue":"1","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imm.12675","volume":"150","author":"E Reeves","year":"2017","unstructured":"Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16\u201324. https:\/\/doi.org\/10.1111\/imm.12675.","journal-title":"Immunology"},{"issue":"12","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941\u20134. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0547.","journal-title":"Cancer Res"},{"key":"1177_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147652.","journal-title":"Int J Mol Sci"},{"key":"1177_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. 2023;14:1190379. https:\/\/doi.org\/10.3389\/fimmu.2023.1190379.","journal-title":"Front Immunol"},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cyto.2016.06.006","volume":"85","author":"C Grimaldi","year":"2016","unstructured":"Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, et al. Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine. 2016;85:101\u20138. https:\/\/doi.org\/10.1016\/j.cyto.2016.06.006.","journal-title":"Cytokine"},{"issue":"3","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy M, Chen J, Dontabhaktuni A, Gaudy A, Kapitanov GI, Li J, et al. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin Pharmacol Ther. 2024;116(3):637\u201346. https:\/\/doi.org\/10.1002\/cpt.3361.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1177_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023;15(1):2181016. https:\/\/doi.org\/10.1080\/19420862.2023.2181016.","journal-title":"MAbs"},{"issue":"5","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481\u201391. https:\/\/doi.org\/10.1200\/JCO.21.00931.","journal-title":"J Clin Oncol"},{"key":"1177_CR10","doi-asserted-by":"crossref","unstructured":"Zhu X (sue), Olabode D, Lai M, Pichardo-Almarza C, Smart K, Brennan D, et al. Exposure-response analysis and quantitative systems pharmacology modeling for optimal RP2D selection of AZD0486 in follicular lymphoma patients. Blood [Internet]. 2024 Nov 5;144(Supplement 1):2794\u20132794. Available from:\u00a0https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/2794\/531843\/Exposure-Response-Analysis-and-Quantitative. Accessed 20 Jul 2025","DOI":"10.1182\/blood-2024-197995"},{"key":"1177_CR11","doi-asserted-by":"publisher","unstructured":"P-075 Development of a Quantitative Systems Pharmacology (QSP) model describing T-cell bispecific induced immune activation and Multiple Myeloma (MM) cell killing. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2024 Sep 1 [cited 2025 Jun 27];24:S85. Available from: https:\/\/doi.org\/10.1016\/S2152-2650(24)01978-5","DOI":"10.1016\/S2152-2650(24)01978-5"},{"issue":"Supplement 1","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2021-147303","volume":"138","author":"KV Komanduri","year":"2021","unstructured":"Komanduri KV, Belousov A, Byrtek M, Kwan A, Perez-Callejo D, Li CC, et al. Development of a predictive model for cytokine release syndrome to inform risk stratification and CRS management following immunotherapy. Blood. 2021;138(Supplement 1):1459\u20131459. https:\/\/doi.org\/10.1182\/blood-2021-147303.","journal-title":"Blood"},{"issue":"6","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/cts.12662","volume":"12","author":"X Chen","year":"2019","unstructured":"Chen X, Kamperschroer C, Wong G, Xuan D. A modeling framework to characterize cytokine release upon T-cell-engaging bispecific antibody treatment: methodology and opportunities. Clin Transl Sci. 2019;12(6):600\u20138. https:\/\/doi.org\/10.1111\/cts.12662.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.xphs.2021.12.019","volume":"111","author":"N Frances","year":"2022","unstructured":"Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, et al. Novel in vivo and in vitro pharmacokinetic\/pharmacodynamic-based human starting dose selection for Glofitamab. J Pharm Sci. 2022;111(4):1208\u201318. https:\/\/doi.org\/10.1016\/j.xphs.2021.12.019.","journal-title":"J Pharm Sci"},{"key":"1177_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696","author":"M Bacac","year":"2016","unstructured":"Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1696.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-22-0201","volume":"21","author":"R Iurlaro","year":"2022","unstructured":"Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, et al. A novel EGFRvIII T-cell bispecific antibody for the treatment of glioblastoma. Mol Cancer Ther. 2022;21(10):1499\u2013509. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0201.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1177_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241091","volume":"16","author":"F Cremasco","year":"2021","unstructured":"Cremasco F, Menietti E, Speziale D, Sam J, Sammicheli S, Richard M, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021;16(1):e0241091. https:\/\/doi.org\/10.1371\/journal.pone.0241091.","journal-title":"PLoS One"},{"issue":"2","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood.2024025987","volume":"145","author":"J Eckmann","year":"2025","unstructured":"Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. 2025;145(2):202\u201319. https:\/\/doi.org\/10.1182\/blood.2024025987.","journal-title":"Blood"},{"issue":"1","key":"1177_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47062-5","volume":"15","author":"E Marrer-Berger","year":"2024","unstructured":"Marrer-Berger E, Nicastri A, Augustin A, Kramar V, Liao H, Hanisch LJ, et al. The physiological interactome of TCR-like antibody therapeutics in human tissues. Nat Commun. 2024;15(1):3271. https:\/\/doi.org\/10.1038\/s41467-024-47062-5.","journal-title":"Nat Commun"},{"key":"1177_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1346502","volume":"14","author":"A Spreafico","year":"2024","unstructured":"Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. Front Oncol. 2024;14:1346502. https:\/\/doi.org\/10.3389\/fonc.2024.1346502.","journal-title":"Front Oncol"},{"issue":"25","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood.2020010477","volume":"138","author":"C Augsberger","year":"2021","unstructured":"Augsberger C, H\u00e4nel G, Xu W, Pulko V, Hanisch LJ, Augustin A, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021;138(25):2655\u201369. https:\/\/doi.org\/10.1182\/blood.2020010477.","journal-title":"Blood"},{"key":"1177_CR22","unstructured":"Center for Drug Evaluation, Research. U.S. Food and Drug Administration. FDA; 2023 [cited 2025 Jun 27]. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. Available from:\u00a0https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell. Accesed 20 Jul 2025"},{"key":"1177_CR23","doi-asserted-by":"publisher","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol [Internet]. 2023 Jun;24(6):e255\u201369. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6.\u00a0Accesed 20 Jul 2025","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"1177_CR24","doi-asserted-by":"crossref","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol [Internet]. 2021 Jun 20;39(18):1959\u201370. Available from:\u00a0https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.03175.\u00a0Accesed 20 Jul 2025","DOI":"10.1200\/JCO.20.03175"},{"key":"1177_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205:114075. https:\/\/doi.org\/10.1016\/j.ejca.2024.114075.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1177_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1177_CR27","unstructured":"The R Project for Statistical Computing [Internet]. [cited 2025 Jun 27]. Available from: https:\/\/www.R-project.org\/"},{"key":"1177_CR28","unstructured":"Comprehensive R Archive Network (CRAN) [Internet]. [cited 2025 Jun 27]. NonCompart: Noncompartmental Analysis for Pharmacokinetic Data. Available from: https:\/\/CRAN.R-project.org\/package=NonCompart"},{"issue":"2","key":"1177_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785\u201395. https:\/\/doi.org\/10.3324\/haematol.2016.150896.","journal-title":"Haematologica"},{"issue":"1","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2005.06.004","volume":"12","author":"W Blum","year":"2006","unstructured":"Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant. 2006;12(1):61\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2005.06.004.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1177_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","volume":"28","author":"Y Gu","year":"2024","unstructured":"Gu Y, Zhao Q. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Mol Diagn Ther. 2024;28(6):669\u2013702. https:\/\/doi.org\/10.1007\/s40291-024-00734-w.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"1177_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/cpt.3439","volume":"117","author":"P Nagaraja Shastri","year":"2025","unstructured":"Nagaraja Shastri P, Shah N, Lechmann M, Mody H, Retter MW, Zhu M, et al. Industry perspective on first-in-human and clinical pharmacology strategies to support clinical development of T-cell engaging bispecific antibodies for cancer therapy. Clin Pharmacol Ther. 2025;117(1):34\u201355. https:\/\/doi.org\/10.1002\/cpt.3439.","journal-title":"Clin Pharmacol Ther"},{"key":"1177_CR34","unstructured":"Center for Drug Evaluation, Research. U.S. Food and Drug Administration. FDA; 2021 [cited 2025 Jun 27]. Bispecific Antibody Development Programs Guidance for Industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bispecific-antibody-development-programs-guidance-industry"},{"key":"1177_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-19","author":"LL Kovanda","year":"2019","unstructured":"Kovanda LL, Sullivan SM, Smith LR, Desai AV, Bonate PL, Hope WW. Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: analysis of a single- and multiple-ascending-dose study in healthy subjects. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00163-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1177_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/cpdd.767","volume":"9","author":"S Tanimoto","year":"2020","unstructured":"Tanimoto S, Pesco Koplowitz L, Lowenthal RE, Koplowitz B, Rabinowicz AL, Carrazana E. Evaluation of pharmacokinetics and dose proportionality of diazepam after intranasal administration of NRL-1 to healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(6):719\u201327. https:\/\/doi.org\/10.1002\/cpdd.767.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"17","key":"1177_CR37","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7(17):4926\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2022009260.","journal-title":"Blood Adv"},{"issue":"6","key":"1177_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13825","volume":"17","author":"B Bender","year":"2024","unstructured":"Bender B, Li CC, Marchand M, Turner DC, Li F, Vadhavkar S, et al. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Transl Sci. 2024;17(6):e13825. https:\/\/doi.org\/10.1111\/cts.13825.","journal-title":"Clin Transl Sci"},{"issue":"287","key":"1177_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802","volume":"7","author":"LL Sun","year":"2015","unstructured":"Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287):287ra70. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4802.","journal-title":"Sci Transl Med"},{"issue":"22","key":"1177_CR40","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"key":"1177_CR41","doi-asserted-by":"publisher","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res [Internet]. 2021 Mar 1;27(5):1526\u201337. Available from: https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2845","DOI":"10.1158\/1078-0432.CCR-20-2845"},{"key":"1177_CR42","doi-asserted-by":"publisher","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9.\u00a0Accesed 20 Jul 2025","DOI":"10.1186\/s40425-018-0343-9"},{"issue":"7","key":"1177_CR43","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jcyt.2022.01.004","volume":"24","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, et al. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy. 2022;24(7):742\u20139. https:\/\/doi.org\/10.1016\/j.jcyt.2022.01.004.","journal-title":"Cytotherapy"},{"key":"1177_CR44","doi-asserted-by":"crossref","unstructured":"Abdelmotaleb O, Schneider A, Hofer T, Sam J, Lechmann M, Waldhauer I, et al. Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on in-vitro potency, in-vivo efficacy, and cytokine release. Cancer Res [Internet]. 2024 Mar 22;84(6_Supplement):1235\u20131235. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/84\/6_Supplement\/1235\/739283\/Abstract-1235-Impact-of-anti-CD3-and-tumor-target","DOI":"10.1158\/1538-7445.AM2024-1235"},{"key":"1177_CR45","doi-asserted-by":"publisher","unstructured":"An G. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 2020;60(2):149\u201363. https:\/\/doi.org\/10.1002\/jcph.1545.\u00a0Accesed 20 Jul 2025","DOI":"10.1002\/jcph.1545"},{"issue":"4","key":"1177_CR46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol [Internet]. 2017;30(4):336\u201340. https:\/\/doi.org\/10.1016\/j.beha.2017.09.002.","journal-title":"Best Pract Res Clin Haematol [Internet]"},{"key":"1177_CR47","unstructured":"Office of the Commissioner. U.S. Food and Drug Administration. FDA; 2025 [cited 2025 Jun 27]. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01177-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:34:07Z","timestamp":1774460047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01177-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01177-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to change corresponding author's email address to work address.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL, CB and NF were employees of F. Hoffmann-La Roche Ltd, Switzerland at the time this work was performed. CB and NF own Roche stocks. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"20"}}